FDA Clears Hyperfine's Next Optive AI Software, Adding 3D Imaging to Portable MRI
HYPR is trading near its 52-week low of $0.85 (6.2% above the low).
Summary
Hyperfine received FDA clearance for its latest Optive AI software update, the second cleared package since the next-gen Swoop system launched in mid-2025. The update adds an isotropic T1 sequence enabling 3D visualization, improves noise cancellation for clearer images in noisy ICU/ED environments, and introduces a more guided scanning workflow. Rollout to U.S. customers begins in September. This expands the clinical utility of the Swoop system and supports future applications like neurosurgery contrast imaging. The company reported Q2 revenue of $3.9 million (up 45% YoY) with $43.5 million in cash, so this clearance is a meaningful product milestone for a small-cap medtech.
At the time of this announcement, HYPR was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $95.6M. The 52-week trading range was $0.85 to $2.22. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.